ArticleEuropean journal of nuclear medicine and molecular imaging2023
Comparison of renal clearance of [
Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Parametric imaging of dynamic long-axial-field-of-view PET scans: Technical challenges, statistical insights and clinical applications.Zeitschrift fur medizinische Physik · 2026Review
- Molecular imaging in gastric cancer: state-of-the-art techniques and emerging opportunities.Journal of translational medicine · 2026Review
- Investigation of aBMC cancer · 2026Article
- AlEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Evaluation of a novelEuropean journal of nuclear medicine and molecular imaging · 2024Article
- Optimized method for fluorine-18 radiolabeling of Affibody molecules using RESCA.EJNMMI radiopharmacy and chemistry · 2024Article
- Cyclohexanediamine Triazole (CHDT) Functionalization Enables Labeling of Target Molecules with AlBioconjugate chemistry · 2024Article
- Non-invasive PET imaging of liver fibrogenesis using a RESCA-conjugated Affibody molecule.iScience · 2024Article
- Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy.Biomedicines · 2024Review
- Advances and challenges in immunoPET methodology.Frontiers in nuclear medicine · 2024Review
- Phase I clinical evaluation ofTheranostics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeA novel HER2 affibody-based molecular probe, [
methodsIn preclinical studies, micro-PET/CT was performed using HER2-positive gastric cancer patient-derived xenografts (PDX) model at 0.5-1 (dynamic), 2, 4, and 6 h post-injection. For blocking experiment, 0.5 mg cold affibody was co-injected with probes. Biodistribution were performed on HER2-positive PDX models at 2 h post-injection. For clinical study, PET/CT images were acquired at 2 h and 4 h after injection of 231.29 ± 17.77 MBq [
results[
conclusions[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.